T1	Treatment 471 538	received a 10-minute intravenous infusion of vernakalant (3 mg/kg).
T2	Treatment 539 670	If after a 15-minute observation period AF was present, a second 10-minute infusion of intravenous vernakalant (2 mg/kg) was given.
T3	Treatment 724 865	patients with recent-onset AF (AF lasting >3 hours to < or =7 days) who converted to SR within 90 minutes of the start of the first infusion.
T4	Treatment 866 1044	Safety evaluations included vital signs, telemetry and Holter monitoring, 12-lead electrocardiography, clinical laboratory tests, physical examinations, and adverse events (AEs).
